Literature DB >> 19782644

The influence of riboflavin photochemistry on plasma coagulation factors.

Luis Larrea1, María Calabuig, Vanesa Roldán, José Rivera, Han-Mou Tsai, Vicente Vicente, Roberto Roig.   

Abstract

UNLABELLED: Studies with riboflavin in the 1960s showed that it could be effective at inactivating pathogens when exposed to light. The principal mode of action is through electron transfer reactions, most importantly in nucleic acids. This suggested that it could act as a photosensitizer useful in the inactivation of pathogens found in blood products.
OBJECTIVE: To study the influence of photo-inactivation with riboflavin on the coagulation factors of plasma.
METHODS: The photo-inactivation procedure of riboflavin plus light was applied. Fifty isogroup pools of two plasmas were made from 100U of plasma that were derived from whole blood products that had previously been held overnight. Pools were split into two bags. One of them was photo-inactivated, and post inactivation samples were obtained. The second bag was not photo-inactivated and samples were taken. Total protein, fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI, FXIII, antithrombin III, PC, PS, alpha-2 antiplasmin and vWF:Ag, the multimeric structure of vWF and ADAMTS-13 were analyzed.
RESULTS: In plasma, the proteins most sensitive to photo-inactivation were fibrinogen, FXI, FVIII, FV, and FIX (33%, 32%, 30%, 18% and 18% loss, respectively). Coagulation inhibitors, PS, antithrombin III and PC showed little decrease (all 2%). Retention of vWF and ADAMTS-13 were 99% and 88%, respectively.
CONCLUSIONS: As with other pathogen reduction procedures for plasma products, treatment with riboflavin and UV light resulted in reduction in the activity levels of several pro-coagulant factors. Coagulation inhibitors are well preserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782644      PMCID: PMC3158998          DOI: 10.1016/j.transci.2009.09.006

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  23 in total

1.  Coagulation factor levels in solvent/detergent-treated plasma.

Authors:  F W Leebeek; M R Schipperus; H H van Vliet
Journal:  Transfusion       Date:  1999-10       Impact factor: 3.157

Review 2.  Determination of factor VIII activity in plasma and concentrates: comparison between methods.

Authors:  Steffen Rosén; Marina Chiarion Casoni
Journal:  Am Clin Lab       Date:  2002-04

Review 3.  Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

Authors:  Lorna M Williamson; Rebecca Cardigan; Chris V Prowse
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

4.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

Authors:  H M Tsai; W L Chandler; R Sarode; R Hoffman; S Jelacic; R L Habeeb; S L Watkins; C S Wong; G D Williams; P I Tarr
Journal:  Pediatr Res       Date:  2001-05       Impact factor: 3.756

5.  Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers.

Authors:  Peter Schlenke; Tor Hervig; Hervé Isola; Marie-Louise Wiesel; Daniel Kientz; Linda Pinkoski; Yasmin Singh; Lily Lin; Laurence Corash; Jean-Pierre Cazenave
Journal:  Transfusion       Date:  2008-01-07       Impact factor: 3.157

Review 6.  Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy.

Authors:  Peter Hellstern; Hannelore Haubelt
Journal:  Thromb Res       Date:  2002-10-31       Impact factor: 3.944

7.  The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma.

Authors:  Margaret Garwood; Rebecca A Cardigan; Olive Drummond; Valerie S Hornsey; Craig P Turner; David Young; Lorna M Williamson; Chris V Prowse
Journal:  Transfusion       Date:  2003-09       Impact factor: 3.157

8.  Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.

Authors:  Patrick H Ruane; Richard Edrich; Deanna Gampp; Shawn D Keil; R Lynne Leonard; Raymond P Goodrich
Journal:  Transfusion       Date:  2004-06       Impact factor: 3.157

9.  Manufacture and in vitro characterization of a solvent/detergent-treated human plasma.

Authors:  P Hellstern; H Sachse; H Schwinn; K Oberfrank
Journal:  Vox Sang       Date:  1992       Impact factor: 2.144

10.  Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.

Authors:  H Yarranton; A S Lawrie; G Purdy; I J Mackie; S J Machin
Journal:  Transfus Med       Date:  2004-02       Impact factor: 2.019

View more
  8 in total

1.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

2.  Inactivation of enveloped virus by laser-driven protein aggregation.

Authors:  Shaw-Wei D Tsen; Travis Chapa; Wandy Beatty; Kong-Thon Tsen; Dong Yu; Samuel Achilefu
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

3.  Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.

Authors:  Susan Yonemura; Lindsay Hartson; Taru S Dutt; Marcela Henao-Tamayo; Raymond Goodrich; Susanne Marschner
Journal:  Vox Sang       Date:  2021-04-09       Impact factor: 2.996

4.  Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation.

Authors:  Shaw-Wei D Tsen; Tzyy Choou Wu; Juliann G Kiang; Kong-Thon Tsen
Journal:  J Biomed Sci       Date:  2012-07-06       Impact factor: 8.410

5.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

6.  Preparation and Storage of Cryoprecipitate Derived from Amotosalen and UVA-Treated Apheresis Plasma and Assessment of In Vitro Quality Parameters.

Authors:  Katarina Kovacic Krizanic; Florian Prüller; Konrad Rosskopf; Jean-Marc Payrat; Silke Andresen; Peter Schlenke
Journal:  Pathogens       Date:  2022-07-18

7.  Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues.

Authors:  Cristina Rosell-Valle; María Martín-López; Fernando Campos; Jesús Chato-Astrain; Rafael Campos-Cuerva; Miguel Alaminos; Mónica Santos González
Journal:  Front Bioeng Biotechnol       Date:  2022-08-23

8.  Rapid inactivation of SARS-CoV-2 with LED irradiation of visible spectrum wavelengths.

Authors:  Riccardo De Santis; Vincenzo Luca; Jonas Näslund; Rosina K Ehmann; Marta De Angelis; Eva Lundmark; Lucia Nencioni; Giovanni Faggioni; Silvia Fillo; Donatella Amatore; Elisa Regalbuto; Filippo Molinari; Giancarlo Petralito; Roman Wölfel; Paola Stefanelli; Gianni Rezza; Anna Teresa Palamara; Markus Antwerpen; Mats Forsman; Florigio Lista
Journal:  J Photochem Photobiol       Date:  2021-10-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.